Across the 2025 to 2034 projection horizon, the worldwide Neuroimmunology Drugs Market is forecasted to register a CAGR of 9.7%.
Neuroimmunology Drugs encompasses The Neuroimmunology Drugs Market is growing very fast, driven by expanding knowledge of the complex interaction between the immune and nervous systems. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
The market's upward path is bolstered by expanding healthcare spending, technological evolution, and the expanding focus on personalized and precision-based approaches in healthcare.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region forecasted to deliver the strongest growth trajectory through the forecast period, bolstered by demographic shifts and policy support.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Neuroimmunology Drugs Market Snapshot
Chapter 4. Global Neuroimmunology Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Global Neuroimmunology Drugs Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Radiopharma Industry Trends
Chapter 5. Neuroimmunology Drugs Market Segmentation 1: By Disease Focus, Estimates & Trend Analysis
5.1. Market Share by Disease Focus, 2023 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Disease Focus:
5.2.1. Multiple Sclerosis (MS)
5.2.2. Neuromyelitis Optica Spectrum Disorder (NMOSD)
5.2.3. Alzheimer's Disease (AD)
5.2.4. Parkinson's Disease (PD)
5.2.5. Amyotrophic Lateral Sclerosis (ALS)
5.2.6. Autoimmune Encephalitis
5.2.7. Other Rare Neuroimmune Disorders
Chapter 6. Neuroimmunology Drugs Market Segmentation 2: By Therapeutic Approach, Estimates & Trend Analysis
6.1. Market Share by Therapeutic Approach, 2023 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Therapeutic Approach:
6.2.1. Monoclonal Antibodies
6.2.2. Bruton's Tyrosine Kinase Inhibitors (BTKIs)
6.2.3. CAR-T Cell Therapies
6.2.4. Small Molecules
6.2.5. Microglia-Targeted Therapies
6.2.6. Gene and Stem Cell Therapies
Chapter 7. Neuroimmunology Drugs Market Segmentation 3: By Mechanism of Action, Estimates & Trend Analysis
7.1. Market Share by Mechanism of Action 2023 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Mechanism of Action:
7.2.1. Immune Cell Depletion
7.2.2. Immune Cell Trafficking Inhibition
7.2.3. Cytokine Modulation
7.2.4. Microglial Regulation
7.2.5. Complement Inhibition
7.2.6. Remyelination and Neuroprotection
Chapter 8. Neuroimmunology Drugs Market Segmentation 4: By Development Stage, Estimates & Trend Analysis
8.1. Market Share by Development Stage, 2023 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Development Stage:
8.2.1. Approved Therapies
8.2.2. Clinical Pipeline (Phase I–III)
8.2.3. Preclinical Innovations
Chapter 9. Neuroimmunology Drugs Market Segmentation 5: By Delivery Method, Estimates & Trend Analysis
9.1. Market Share by Delivery Method, 2023 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Delivery Method:
9.2.1. Systemic (IV, Subcutaneous, Oral)
9.2.2. CNS-Targeted (Intranasal, Intrathecal, Nanoparticle-Based)
9.2.3. Cell-Based
Chapter 10. Neuroimmunology Drugs Market Segmentation 6: By Biomarker Integration, Estimates & Trend Analysis
10.1. Market Share by Biomarker Integration, 2023 & 2034
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 & 2034 for the following Biomarker Integration:
10.2.1. Diagnostic Biomarkers
10.2.2. Predictive Biomarkers
10.2.3. Monitoring Biomarkers
Chapter 11. Neuroimmunology Drugs Market Segmentation 7: Regional Estimates & Trend Analysis
11.1. Global Neuroimmunology Drugs Market, Regional Snapshot 2023 & 2034
11.2. North America
11.2.1. North America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.2.1.1. US
11.2.1.2. Canada
11.2.2. North America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease Focus, 2021-2034
11.2.3. North America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Approach, 2021-2034
11.2.4. North America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mechanism of Action 2021-2034
11.2.5. North America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Development Stage, 2021-2034
11.2.6. North America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
11.2.7. North America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Biomarker Integration, 2021-2034
11.3. Europe
11.3.1. Europe Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.3.1.1. Denmark
11.3.1.2. Finland
11.3.1.3. Austria
11.3.1.4. France
11.3.1.5. Germany
11.3.1.6. Israel
11.3.1.7. Italy
11.3.1.8. Netherlands
11.3.1.9. Norway
11.3.1.10. Poland
11.3.2. Europe Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease Focus, 2021-2034
11.3.3. Europe Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Approach, 2021-2034
11.3.4. Europe Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mechanism of Action 2021-2034
11.3.5. Europe Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Development Stage, 2021-2034
11.3.6. Europe Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
11.3.7. Europe Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Biomarker Integration, 2021-2034
11.4. Asia Pacific
11.4.1. Asia Pacific Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.4.1.1. Australia
11.4.1.2. China
11.4.1.3. India
11.4.1.4. Indonesia
11.4.1.5. Japan
11.4.1.6. Malaysia
11.4.1.7. Philippines
11.4.1.8. Singapore
11.4.1.9. South Korea
11.4.1.10. Taiwan
11.4.1.11. Thailand
11.4.1.12. Rest of APAC
11.4.2. Asia Pacific Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease Focus, 2021-2034
11.4.3. Asia Pacific Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Approach, 2021-2034
11.4.4. Asia Pacific Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts By Mechanism of Action 2021-2034
11.4.5. Asia Pacific Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Development Stage, 2021-2034
11.4.6. Asia Pacific Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
11.4.7. Asia Pacific Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Biomarker Integration, 2021-2034
11.5. Latin America
11.5.1. Latin America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.5.1.1. Argentina
11.5.1.2. Brazil
11.5.1.3. Mexico
11.5.1.4. Rest of LATAM
11.5.2. Latin America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease Focus, 2021-2034
11.5.3. Latin America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Approach, 2021-2034
11.5.4. Latin America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mechanism of Action 2021-2034
11.5.5. Latin America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Development Stage, 2021-2034
11.5.6. Latin America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
11.5.7. Latin America Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Biomarker Integration, 2021-2034
11.6. Middle East & Africa
11.6.1. Middle East & Africa Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
11.6.1.1. Egypt
11.6.1.2. Israel
11.6.1.3. Nigeria
11.6.1.4. Saudi Arabia
11.6.1.5. Qatar
11.6.1.6. United Arab Emirates
11.6.1.7. Rest of MEA
11.6.2. Middle East & Africa Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Disease Focus, 2021-2034
11.6.3. Middle East & Africa Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Approach, 2021-2034
11.6.4. Middle East & Africa Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mechanism of Action 2021-2034
11.6.5. Middle East & Africa Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Development Stage, 2021-2034
11.6.6. Middle East & Africa Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
11.6.7. Middle East & Africa Neuroimmunology Drugs Market Revenue (US$ Million) Estimates and Forecasts by Biomarker Integration, 2021-2034
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. Roche
12.2.1.1. Business Overview
12.2.1.2. Key Product/Service
12.2.1.3. Financial Performance
12.2.1.4. Modeance
12.2.1.5. Geographical Presence
12.2.1.6. Recent Developments with Business Strategy
12.2.2. Biogen
12.2.3. Sanofi
12.2.4. Novartis
12.2.5. Merck KGaA
12.2.6. Bristol Myers Squibb
12.2.7. AstraZeneca (Alexion)
12.2.8. Eli Lilly
12.2.9. UCB
12.2.10. Kyverna Therapeutics
12.2.11. Abata Therapeutics
12.2.12. Vigil Neuroscience
12.2.13. Denali Therapeutics
12.2.14. Takeda
12.2.15. Amgen
12.2.16. GSK
12.2.17. Sarepta Therapeutics
12.2.18. Neurona Therapeutics